India · Delayed Price · Currency is INR Fortis Healthcare Earnings Call Transcripts
Fiscal Year 2026
-
Strong revenue and profit growth in FY 2026 driven by hospital and diagnostic segments, with robust expansion plans and margin improvement guidance for FY 2027. Strategic investments, new bed additions, and focus on clinical quality position the business for sustained growth.
-
Q3 FY26 saw 17.5% revenue growth and 34.8% EBITDA growth, with margin expansion across hospital and diagnostics segments. Key developments include major acquisitions, robust digital revenue growth, and a strong M&A pipeline focused on cluster expansion.
-
Q2 FY26 saw 17.3% revenue growth and 28% EBITDA increase, driven by strong hospital and diagnostics performance, margin expansion, and successful acquisitions. Occupancy and ARPOB improved, with robust digital and international growth. Legal and structural simplification underway.
-
Q1 FY2026 saw 16.6% revenue growth and 43.2% EBITDA increase, driven by hospital and diagnostics expansion, improved specialty mix, and digital initiatives. Margin guidance remains at 22–23%, with strong brownfield ramp-up and new O&M agreements supporting future growth.
Fiscal Year 2025
-
FY25 saw 12.9% revenue growth, 25.3% EBITDA growth, and margin expansion, led by hospitals. Strategic acquisitions, digital growth, and bed additions support a positive FY26 outlook with further margin and revenue gains expected.
-
Q3 FY25 delivered 14.8% revenue growth and 32% higher EBITDA, driven by strong hospital performance and specialty mix. Diagnostic margins improved, with rebranding costs set to taper off. CapEx and expansion remain focused on brownfield projects, with margin and growth guidance maintained.
-
Q2 FY25 saw 12.3% revenue growth and a 31.9% rise in operating EBITDA, with hospital and diagnostic segments both delivering margin expansion. Brownfield expansions, digital initiatives, and the Agilus stake acquisition are set to drive future growth.
-
Q1 FY25 delivered double-digit revenue and profit growth, with hospital business margins expanding and digital channels contributing significantly. Diagnostic margins were impacted by one-offs, but wellness and genomics segments showed robust growth. Brownfield expansions and Agilus stake buyout are on track.